Previous 10 | Next 10 |
Best Penny Stocks To Buy? 7 To Watch With Big Headlines In January 2023 Are you ready to get the ball rolling with penny stocks in 2023? You’re not alone, but unlike other years, chances are we’ll see much more volatility in the stock market. Heightened concerns over inflation, ...
Clinical-stage biotech Geron Corporation ( NASDAQ: GERN ) jumped ~64% pre-market Wednesday after announcing topline data from its IMerge Phase 3 clinical trial for its only candidate imetelstat, in lower-risk myelodysplastic syndromes (MDS) patients. The 178-subject global trial i...
Geron Corporation (Nasdaq: GERN) today announced that it will host a conference call to discuss top-line results from the IMerge Phase 3 clinical trial of imetelstat, the Company’s first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS) on January 4, 2023, at 8:0...
≥1 year durable transfusion independence (1-year TI) achieved in 29% of IMerge Phase 2 patients, with a median TI duration of 1.8 years In patients previously treated with luspatercept, 33% achieved 1-year TI Strong evidence of disease modification in patients with 1-year TI as ind...
Hot Penny Stocks To Watch With The Stock Market Down Today The stock market is down today, but that doesn’t mean all stocks are getting dumped. In fact, in this article, we discuss a handful of bullish names trading higher in a sea of red. What’s helping them stay afloat? Big ne...
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to partici...
Image source: The Motley Fool. Geron (NASDAQ: GERN) Q3 2022 Earnings Call Nov 03, 2022 , 9:00 a.m. ET Aron Feingold Continue reading For further details see: Geron (GERN) Q3 2022 Earnings Call Transcript
Geron Corporation (GERN) Q3 2022 Results Conference Call November 03, 2022 09:00 AM ET Company Participants Aron Feingold - Vice President of Investor Relations and Corporate Communications John Scarlett - Chairman and Chief Executive Officer Olivia Bloom - Execu...
Geron Corp ( NASDAQ: GERN ) is trading ~3% lower after the company missed Q3 GAAP EPS, as costs increased during the quarter. Revenue rose 172% Y/Y to $0.3M, and beat by $0.21M. While, Q3 GAAP EPS of -$0.10 missed by $0.01. Research and development costs w...
Updated imetelstat data from IMerge Phase 2 describe significant continuous durable transfusion independence, meaningful reduction in mutational burden and progression-free survival, which indicate disease-modifying activity Ongoing Phase 3 IMerge clinical trial of imetelstat desi...
News, Short Squeeze, Breakout and More Instantly...
RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible (serum EPO >500 mU/mL) Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart the Company on August 31, 2024, to ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company ...